The Future of Metastatic Urothelial Carcinoma Management
Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.
Optimizing Selection of ADC Therapy in Metastatic Urothelial Carcinoma
Focused discussion on the optimal selection and use of antibody-drug conjugate therapies in patients with metastatic urothelial carcinoma.
Sequencing Therapy Through Multiple Lines of Metastatic Urothelial Carcinoma
Expert perspectives on treatment sequencing pathways in metastatic urothelial carcinoma, with deference to recent trial data for both IO and ADC therapies.
Clinical Scenario 1: A 73-Year-Old Man With Metastatic Urothelial Carcinoma
The panel reviews a clinical scenario of metastatic urothelial carcinoma where the patient is not eligible for cisplatin treatment.
Metastatic Urothelial Carcinoma: Optimizing Maintenance Therapy After Chemo
A comprehensive review of maintenance therapy strategies following chemotherapy in the context of optimizing patient outcomes.
Clinical Scenario 1: A 63-Year-Old Woman With Metastatic Urothelial Carcinoma
Centering discussion on a clinical scenario of metastatic urothelial carcinoma, panelists determine which first-line regimen they would utilize prior to maintenance therapy.
Metastatic Urothelial Carcinoma Maintenance Therapy Data
A panel of experts reviews key clinical trial data supporting use of maintenance therapy in metastatic urothelial carcinoma.
Benefit of Maintenance Therapy in Metastatic Urothelial Carcinoma
Shared insight on the broader benefits of maintenance therapy in metastatic urothelial carcinoma and the mainstay agents in this setting.
Metastatic Urothelial Carcinoma: Overview of Treatment Options
Expert oncologists provide a comprehensive overview of treatment options available to patients with metastatic urothelial carcinoma.
Treatment Options for Localized Bladder Cancer
A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.
Overview on Urothelial Carcinoma: Risk Factors, Symptoms, and Staging
Opening their discussion on urothelial carcinoma management, panelists highlight risk factors, symptoms, and staging practices in this setting.
Future Treatment Landscape of Metastatic Urothelial Carcinoma
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
Selecting Second-Line Therapy for Metastatic Urothelial Carcinoma
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
mUC: Duration of Maintenance Avelumab and Treatment at Progression
Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.
Metastatic Urothelial Carcinoma: Does FGFR Status Impact Use of Maintenance Avelumab?
A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.
Metastatic Urothelial Carcinoma: Discussing Maintenance Therapy With Patients
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
When to Use Maintenance Therapy in Metastatic Urothelial Carcinoma
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
Metastatic Urothelial Carcinoma: Experience With Maintenance Avelumab
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
Frontline Immunotherapy for Metastatic Urothelial Carcinoma
Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.
Metastatic Urothelial Carcinoma: Optimizing Frontline Maintenance Therapy
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
Selecting Frontline Therapy for Metastatic Urothelial Carcinoma
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
2 Clarke Drive Cranbury, NJ 08512